GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

Genenta Science SpA ADR GNTA · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.99

+20.62%

Close of 3 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Genenta Science SpA ADR

Its shares trade under the ticker GNTA. It has been listed since 15 December 2021.

Genenta Science S.p.A., a clinical-stage biotechnology company, develops hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company offers Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is developing Temferon for use in the treatment of other solid tumor indications. In addition, the company develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
15 Dec 2021
Employees
9
Website
genenta.com ↗
Head office
OLGETTINA, NO. 58, MILAN, L6, 20132
Incorporated in
L6
Classification
Biological Products, (No Diagnostic Substances)
Filer status
Non-accelerated filer<br>Emerging growth company

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Genenta Science's Temferon is in Phase 1/2a trials for glioblastoma multiforme treatment in Italy.
  • The company's biologic platform targets tumor infiltration using monocytes/macrophages in Italy.
  • Genenta Science has a clinical-stage focus with nine employees in Milan, Italy.

Weaknesses

  • Genenta Science has only nine employees, limiting operational capacity in Milan.
  • The company's clinical-stage development lacks commercialization experience in the US market.
  • Temferon is only in Phase 1/2a trials, indicating early-stage development.

Opportunities

  • Temferon's potential for solid tumor indications could expand into new markets in Italy.
  • The biologic platform may attract partnerships for immunomodulatory treatments in Europe.
  • Genenta Science's focus on hematopoietic stem cell therapies aligns with growing Health Care demand.

Threats

  • Phase 1/2a trials for Temferon face potential regulatory hurdles in the US market.
  • Competition in hematopoietic stem cell therapies could emerge from larger biotech firms.
  • The company's small size may hinder fundraising for advanced clinical trials.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.